BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | BeOne Medicines

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Beigene Study ID

BGB-3111-213

ClinicalTrials.gov ID

NCT03520920

China Drug Trials ID

CTR20170965

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Study Protocol Statistical Analysis Plan